Abbott Laboratories (NYSE:ABT) and Medtronic (NYSE:MDT) are both prominent names in the Medtech space. Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes.
Medtronic (NYSE:MDT), meanwhile, continued to build on its turnaround, reporting its strongest annual revenue growth in a decade as several high-growth platforms gained momentum. So, which is the more compelling long-term investment opportunity: Abbott’s (NYSE:ABT) consistent execution or Medtronic’s (NYSE:MDT) improving growth trajectory?
A patient viewing their medical diagnosis on a digital healthcare ecosystem.
Bull Case
Abbott’s (NYSE:ABT) second-quarter results reinforced one of the company’s biggest competitive advantages: its ability to generate growth from multiple businesses simultaneously. While investors often focus on its medical device portfolio, diagnostics emerged as one of the strongest contributors during the quarter. Sales in its diagnostics segment rose 42% to $3.09 billion in fiscal Q2, surpassing the estimate of $3.02 billion, emerging as one of the company’s strongest performers during the quarter. Its cancer diagnostics business, which was recently integrated through the Exact Sciences buyout, is benefiting from an expanding base that comprises both new and repeat users of the colorectal cancer screening test, Cologuard.
Furthermore, Abbott Laboratories (NYSE:ABT) reaffirmed its full-year 2026 comparable sales growth guidance of 6.5% to 7.5%, suggesting confidence in its operations. The company also raised its full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to the previous range of $5.38 to $5.58.
While Abbott’s (NYSE:ABT) investment case centers on diversification and consistent execution, Medtronic’s (NYSE:MDT) appeal increasingly lies in whether its long-awaited turnaround is finally taking hold.
One of the most prominent factors supporting Medtronic’s (NYSE:MDT) turnaround story is the company’s reporting of its highest annual revenue growth in 10 years in its fiscal Q4 and full-year 2026 results. Q4 revenue reached $9.8 billion, up 9.9% as reported and 6.6% organic, and FY 26 revenue was $36.4 billion, adjusted revenue of $36.3 billion, up 8.4% as reported and 5.8% organic. Those results suggest Medtronic’s (NYSE:MDT) recovery is becoming increasingly broad-based rather than relying on a single product cycle, an important distinction for investors evaluating whether the turnaround is sustainable, especially in its highest growth opportunities such as Affera, Symplicity, Hugo, Altaviva, and Stealth AXiS.
Beyond the headline numbers, Medtronic’s (NYSE:MDT) newer growth platforms are continually gaining traction. Symplicity Spyral for hypertension is now annualizing at approximately $100 million in revenue, while products such as Hugo and Affera continue expanding the company’s exposure to faster-growing MedTech markets. BTIG also recently argued that improving sentiment across the broader MedTech sector could provide an additional tailwind if utilization trends remain healthy.
Bear Case
Abbott’s (NYSE:ABT) second-quarter results were undoubtedly strong, but the company’s full-year outlook still relies on a stronger second half. While management raised its adjusted EPS guidance, it reaffirmed rather than increased its comparable sales growth outlook of 6.5% to 7.5%, suggesting that it remains measured on the pace of revenue growth. The company is also counting on several pipeline products to contribute more meaningfully in the second half of 2026 and into fiscal 2027. If those launches ramp more slowly than expected, the acceleration implied by management’s outlook could prove more difficult to achieve.
Similarly, Medtronic’s (NYSE:MDT) recent results suggest its turnaround is gaining momentum, but investors should still monitor how broadly that improvement spreads across the business. Much of the company’s recent growth has been driven by a handful of newer platforms, including Affera, Hugo, and Symplicity. While those businesses are performing well, the investment case will become more compelling if stronger growth extends across a larger portion of the portfolio. At the same time, competition remains intense in cardiovascular devices and robotic surgery, while management expects tariffs to create an approximately $250 million headwind in fiscal 2027, adding further pressure on margins.
Tariffs are another important factor for investors to monitor. Management stated that they affected Medtronic’s (NYSE:MDT) business by $74 million, representing an 80 basis points headwind. They are anticipated to continue affecting gross margins, with fiscal year 2027 embedding an impact of around $250 million with no assumed refunds.
Valuation and Hedge Fund Positioning
Abbott Laboratories (NYSE:ABT) currently trades at a forward P/E of 19.54, representing a 1.32% premium to the sector. Medtronic (NYSE:MDT), meanwhile, trades at a forward P/E of 14.65, or 24.03% below the sector average. The valuation gap may suggest that investors are willing to pay a higher multiple for Abbott’s (NYSE:ABT) more diversified business model and consistent earnings profile, while assigning a more cautious valuation to Medtronic (NYSE:MDT) as its turnaround story continues to develop.
Institutional positioning paints a similar picture. According to Insider Monkey’s database of 1,022 hedge funds, Abbott’s (NYSE:ABT) hedge fund ownership increased modestly from 71 funds at the end of Q4 2025 to 73 funds in Q1 2026. Medtronic (NYSE:MDT), by contrast, saw hedge fund ownership decline from 63 funds to 60 over the same period. While the changes are relatively small, they suggest institutional sentiment remained slightly more constructive toward Abbott (NYSE:ABT) during the quarter.
Both companies delivered encouraging results, but they represent different investment profiles. Abbott (NYSE:ABT) continues to benefit from the stability that comes with a diversified healthcare portfolio, where strength in diagnostics, medical devices, and nutrition could offset temporary weakness elsewhere. Medtronic (NYSE:MDT), by contrast, offers a classic turnaround story. Its recent results suggest years of investment in high-growth platforms are beginning to translate into faster revenue growth, but investors still need evidence that the recovery can be sustained across a broader range of businesses. As a result, Abbott (NYSE:ABT) may appeal more to investors seeking consistent execution, while Medtronic (NYSE:MDT) could offer greater upside if its turnaround continues gaining momentum.
While we acknowledge the risk and potential of MDT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MDT and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey on Google News.
